Introduction {#Sec1}
============

The progress of congenital heart disease (CHD) surgical interventions over the past few decades has allowed more children to survive well into adulthood. Most of these patients will require multiple surgical procedures over their lifetime. This can be associated with increased morbidity and mortality \[[@CR1], [@CR2]\] due to chest adhesions, bleeding, cardiac ischemia, arrhythmia burden, heart failure, and multi-organ dysfunction \[[@CR3]--[@CR7]\]. Since the introduction of the first balloon expandable valve in the pulmonary position by Bonhoeffer et al \[[@CR8]\] in 2000, advances in interventional cardiology and percutaneous valve replacement have revolutionized the management of these patients. The availability of these minimally invasive and effective therapies may allow for earlier treatment of right-sided valvular disease before the onset of irreversible ventricular remodeling and dysfunction. Moreover, transcatheter options can reduce the need for multiple surgical interventions over a patient's lifetime, therefore affecting the morbidity of this growing patient population \[[@CR9]\]. We herein discuss the impact of existing and future catheter-based valve implantation techniques for dysfunctional right-sided valves.

Pathophysiology and Clinical Presentation of Right-sided Valvular Dysfunction in Congenital Heart Disease {#Sec2}
=========================================================================================================

Pulmonary Valve {#Sec3}
---------------

Pulmonary valve disease in the congenital population can be native or post-operative. Native pulmonary valve dysfunction may be isolated, as in congenital pulmonary stenosis, or may be a part of a recognized condition such as tetralogy of Fallot. Surgical valve or conduit placement is often not performed in infancy or early childhood in preference to procedures that alleviate pulmonic stenosis such as pulmonary valvotomy and subannular or transannular patch placement. These techniques invariably leave the patient with chronic severe pulmonary regurgitation. Surgical pulmonary valve interventions usually consist of valve replacement with either bioprosthetic valves or valved conduits. Rarely, patients may undergo mechanical pulmonic valve replacement. Bioprosthetic valves and conduits (usually homografts) invariably develop progressive dysfunction within 10--20 years of implantation with resultant stenosis and/or regurgitation \[[@CR10]--[@CR12]\].

Although pulmonary valve dysfunction is generally well tolerated, patients often develop progressive exertional limitations and may develop ventricular and supraventricular arrhythmias. Decompensated congestive heart failure is a late manifestation that usually occurs well after the development of exertional symptoms. In patients with progressive stenosis, right ventricular hypertrophy develops as a compensatory mechanism for the increased pressure with resultant right ventricular diastolic dysfunction and eventually systolic dysfunction ensues \[[@CR13]\]. Severe chronic pulmonary regurgitation results in right ventricular volume overload which leads to ventricular dilatation, progressive systolic and diastolic dysfunction, and tricuspid regurgitation due to annular dilatation \[[@CR14]\]. Ventricular and atrial arrhythmias are likely to occur in patients with both stenosis and regurgitation and result in an increased risk of sudden death in this population \[[@CR7], [@CR15]\].

The timing of pulmonary valve replacement in these patients is controversial \[[@CR16], [@CR17]\]. Several studies have evaluated the timing of pulmonary valve replacement in patients with severe chronic pulmonary regurgitation and have suggested that normalization of right ventricular volume will not occur in patients with severely dilated right ventricles (right ventricular end-diastolic volume (RVEDV) \>150 ml/m^2^ or right ventricular end-systolic volume (RVESV) \>80 ml/m^2^) \[[@CR18]--[@CR23]\]. Therefore, it is generally recommended that patients undergo pulmonary valve replacement prior to severe right ventricular dilation or systolic dysfunction. However, there is little evidence that such an approach results in improved clinical outcomes, such as reduced arrhythmia burden or decreased mortality. Furthermore, it is not clear that different etiologies of pulmonic regurgitation behave in the same pathophysiological manner, and thus thresholds developed for regurgitation following repair of tetralogy of Fallot may not apply to those patients with initial isolated pulmonic stenosis \[[@CR24]\]. It does appear likely that earlier PVR results in improved exercise tolerance, especially in patients with predominant pulmonary stenosis \[[@CR17], [@CR25]\].

Tricuspid Valve {#Sec4}
---------------

Native tricuspid valve dysfunction in patients with congenital heart disease is often associated with Ebstein anomaly, which may result in chronic severe tricuspid regurgitation. Severe tricuspid regurgitation is often well tolerated for decades. However, much like pulmonic regurgitation, eventual clinical sequelae will emerge. These include the development of ventricular and supraventricular arrhythmias, elevated central venous pressure with resultant multi-organ congestion (congestive hepatopathy, renal dysfunction, splenomegaly), and progressive right ventricular dysfunction. Native tricuspid valve regurgitation may occur as a result of progressive right ventricular and tricuspid annular dilation or in patients with severely elevated right ventricular systolic pressure due to severe pulmonary hypertension or right ventricular outflow obstruction. Therefore, it is common for patients with RVOT dysfunction, as in repaired tetralogy of Fallot or pulmonic stenosis, to develop secondary tricuspid regurgitation. Surgical techniques for tricuspid valve repair include the placement of annular bands or rings as well as more complex operations to relocate or augment the tricuspid valve leaflets (as in Ebstein's). Progressive tricuspid regurgitation is common during long-term follow-up of these patients and manifests in a similar clinical manner to native tricuspid regurgitation. If surgical valve replacement is warranted, bioprosthetic valves are preferred, although there is limited data on the safety and efficacy of mechanical prostheses. Bioprosthetic tricuspid valves can become dysfunctional over time and generally require replacement within a decade. Progressive regurgitation and/or stenosis may occur with the clinical sequelae of elevated central venous pressure and reduced cardiac output \[[@CR26], [@CR27]\].

Diagnostic Methods of Right-Sided Valvular Disease in Congenital Heart Disease {#Sec5}
==============================================================================

Echocardiography {#Sec6}
----------------

Echocardiography is a widely available and cost-effective tool for the assessment of congenital cardiac structure and function. It is universally utilized for the diagnosis of stenotic or regurgitant valvular lesions using qualitative measures such as color Doppler (Fig. [1](#Fig1){ref-type="fig"}), and density and contour of regurgitant signals, as well as quantitative measures such as vena contracta, effective regurgitant orifice area, and velocity of flow. The echocardiographic exam for right-sided heart lesions also includes assessment of right and left ventricular size and function, right ventricular outflow tract (RVOT) and tricuspid annular dimensions, pulmonary arterial pressure, right and left atrial filling pressures, and systemic and pulmonary blood flow \[[@CR28]--[@CR31]\]. The addition of 3D echo imaging facilitates the quantitative assessment of right ventricular volume and ejection fraction. The use of tissue Doppler and speckle tracking for assessment of systolic and diastolic function, including regional and global right ventricular strain, is an area of growing interest \[[@CR32]\]. Echocardiography typically provides excellent visualization of the tricuspid valve but is less optimal for imaging the pulmonic valve, especially in adult patients. Moreover, echocardiography is widely utilized for the assessment of prosthetic valve function. The comprehensive use of a non-invasive and cost-effective tool such as echocardiography has obviated the need for diagnostic invasive catheterization in most patients with congenital heart disease.Fig. 1**a** Transthoracic echocardiographic image (parasternal short axis view) of the right ventricular outflow tract (RVOT) showing turbulent color Doppler flow across a stenotic pulmonary valve. AV = aortic valve. **b** Parasternal short axis view of RVOT with an indwelling stent in the main pulmonary artery well above the level of the pulmonary valve annulus and color Doppler flow showing severe pulmonary valve regurgitation (PR). Note the regurgitant reverse color Doppler flow in the left pulmonary artery (LPA) and right pulmonary artery (RPA). **c** Parasternal short axis view of the RVOT showing a Melody valve successfully deployed in the MPA

Computed Tomography Angiography {#Sec7}
-------------------------------

Cardiac tomography angiography (CTA) has become an integral part of the evaluation of patients with aortic valve disease prior to transcatheter aortic valve replacement (TAVR). CTA is not as widely utilized for the evaluation of patients with congenital heart disease, as many centers prefer to use cardiac MRI due to concerns over radiation and its limitations in functional assessment due to the lack of blood velocity measurements. Also, CTA requires the injection of iodinated contrast, which is nephrotoxic, and therefore the use of this modality is limited in patients with advanced renal dysfunction. However, ECG-gated chest CTA can provide excellent spatial and temporal resolution and is extremely useful in the assessment of right ventricular outflow tract abnormalities, both native and post-operative \[[@CR33]\]. Moreover, CTA allows for visualization of the coronary arterial anatomy and its relationship to the right ventricular outflow tract and pulmonary artery. Therefore, CTA can be a useful tool for procedural planning in patients with congenital valvular heart disease \[[@CR34]\]. The advent of 3D printing from cross-sectional imaging data allows for individualized planning of complex structural interventions \[[@CR35]\].

Cardiac Magnetic Resonance Imaging {#Sec8}
----------------------------------

Cardiac Magnetic Resonance Imaging (CMR) is widely used for the assessment of congenital heart disease, as it provides anatomic data as well as qualitative and quantitative measurements of valvular regurgitation and/or stenosis. In addition, it provides accurate ventricular dimensions and function. CMR is especially useful for measuring pulmonary regurgitant volume and right ventricular volumes, which are critical parameters for determining the optimal timing for intervening on pulmonary valve regurgitation \[[@CR36]--[@CR39]\]. CMR is non-invasive and does not expose patients to radiation; however, it is time consuming, not universally available, and more expensive than echocardiography and is contraindicated in some patients with pacemakers and defibrillators.

Cardiac Catheterization and Invasive Angiography {#Sec9}
------------------------------------------------

Diagnostic cardiac catheterization was once utilized universally in patients with congenital heart disease but has been supplanted over the past 30 years by the aforementioned non-invasive imaging tools. In cases where the non-invasive data is inconclusive or contradictory, diagnostic catheterization may be necessary. In patients with right-sided congenital valvular disease, catheterization provides direct pressure measurements, facilitates angiography, and allows for accurate measurement of shunts. Moreover, in patients with pulmonary hypertension, catheterization allows for the calculation of pulmonary arterial resistance and determination of pulmonary vasoreactivity. Additionally, invasive hemodynamic assessment during steady state alterations, such as volume loading, stress testing, or infusion of inotropic medications can provide valuable information. That being said, the majority of patients today undergo invasive catheterization mainly for interventional purposes; however, the hemodynamic data gathered pre- and post-intervention is integral to their management.

Catheter-Based Therapies {#Sec10}
========================

Indications for intervention are often based on symptomatology, severity of the stenosis or regurgitation, right ventricular volume and function, and the burden of arrhythmias \[[@CR22], [@CR38], [@CR40]\].

Pulmonary Valve {#Sec11}
---------------

Transcatheter pulmonary valve (TCPV) replacement can alleviate RVOT conduit dysfunction whether due to stenosis, regurgitation, or both, thereby delaying the need for open heart surgery and essentially decreasing the number of operations with their associated morbidities \[[@CR41], [@CR42]\]. The Melody (Medtronic) TCPV was the first valve to receive FDA approval, initially under humanitarian device exemption in 2010 and thereafter for clinical use in 2014. The Melody valve is widely used for the treatment of dysfunctional right ventricular to pulmonary artery (RV-PA) conduits and bioprosthetic valves and more recently has been used to treat dysfunctional native RVOT lesions (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). Due to the size of the deployment system (22 Fr), when used via a transvenous approach, it is restricted to patients weighing more than 20--30 kg \[[@CR41], [@CR43]\]. This limitation does not apply when a hybrid surgical approach is utilized. Currently, the first generation Sapien (Edwards Lifesciences) TCPV is under investigation, also with a 22- and 24-F system (COMPASSION Clinical Trial NCT00676689). The later generations of the Sapien valve (Sapien XT and Sapien 3) are FDA-approved for use in the aortic position and are being used by multiple centers for off-label implantation in the pulmonary position (Fig. [4](#Fig4){ref-type="fig"}). The larger-diameter Sapien valves (26 and 29 mm) allow for implantation in large dysfunctional native RVOTs. The Sapien XT is also under clinical investigation currently for the pulmonary position (COMPASSION III Clinical Trial NCT02302131).Fig. 2**a** Antero-posterior (AP) angiographic view of a bioprosthetic pulmonary valve (BPV) with contrast injection in the pulmonary artery showing severe pulmonary regurgitation and a stent in the right pulmonary artery. **b** AP view of the same bioprosthetic valve after transcatheter pulmonary valve placement (TPV) of a Melody valve. No residual pulmonary regurgitation is seenFig. 3**a** Antero-posterior and cranial projection of a contrast injection into the main pulmonary artery (MPA) demonstrating severe pulmonary regurgitation into the native right ventricular outflow tract (RVOT). The right and left pulmonary arteries (RPA and LPA) are labeled, with a narrowing just proximal to the branching of the MPA measuring approximately 14.9 mm. Note sternal wires from previous median sternotomy. **b** Bare metal stent placed across the narrowed MPA. **c** Image following Melody transcatheter pulmonary valve (TPV) placement within the stent. Contrast injection in the MPA shows no residual pulmonary regurgitationFig. 4**a** Lateral angiographic view of a native right ventricular outflow tract (RVOT) with a wire placed in the distal left pulmonary artery and catheter in a dilated main pulmonary artery (MPA) showing severe regurgitation across a dysfunctional native pulmonary valve (PV). **b** Antero-posterior (AP) angiographic view of the same native RVOT showing severe PR. **c** AP fluoroscopic view of the Sapien XT transcatheter pulmonary valve (TPV) positioned within a stent across the native pulmonary valve. **d** Lateral view of the Sapien valve delivery system positioned across the pre-stented PV. **e** AP view of deployed Sapien valve within the stented PV. **f** Lateral view of the deployed Sapien valve within the pre-stented PV

Short-term outcomes of the Melody valve have proven the durability of the valve \[[@CR44]--[@CR50]\]. Furthermore, there is significant hemodynamic and clinical improvements after Melody valve placement due to right ventricular remodeling, decrease in end diastolic volumes, increase in cardiac output, and subsequently an improvement in exercise tolerance \[[@CR17], [@CR25], [@CR44], [@CR48], [@CR49], [@CR51]--[@CR54], [@CR55]•\]. This effect is seen more significantly in patients with RVOT obstruction and/or regurgitation versus those with only regurgitant lesions \[[@CR25]\]. Favorable longer-term outcomes were seen after a median follow-up of 4.5 years in 148 patients in the US melody valve investigational device exemption trial, with a 5-year freedom from re-intervention of 76 % and a 5-year freedom from explant of 92 % \[[@CR56]\].

Stent fracture and endocarditis have been the primary causes for re-intervention \[[@CR47], [@CR55]•, [@CR57], [@CR58], [@CR59]•\]. Stent fracture often occurs in patients with conduits or native RVOT dysfunction and is likely due to repetitive stress on the platinum iridium frame. Pre-stenting before Melody valve placement has significantly reduced the incidence of stent fracture. Also, valve-in-valve implantation is a successful treatment option for Melody valve stent fracture (Fig. [5](#Fig5){ref-type="fig"}) \[[@CR47], [@CR55]•, [@CR60]--[@CR62]\]. As for endocarditis, adherence with SBE prophylaxis is imperative; however, data suggests there is an increased risk of infective endocarditis with implanted Melody valves \[[@CR57], [@CR58], [@CR59]•\]. Other complications such as conduit or pulmonary artery dissection or rupture are life threatening but rare and can be treated with covered stent placement. There is a 5 % risk of coronary artery compression, but this risk can be reduced by performing simultaneous balloon inflation in the RVOT with coronary or aortic root angiography to test for coronary artery compression (Fig. [6](#Fig6){ref-type="fig"}) \[[@CR63]\]. Aortic compression may also occur in this population (Fig. [7](#Fig7){ref-type="fig"}). Lastly, valve embolization is a rare risk; which can be averted by adequate pre-procedural planning and RVOT sizing. However, when it does occur and the valve cannot be safely deployed in a distal pulmonary artery branch or vena cava, surgical removal may be necessary.Fig. 5**a** Antero-posterior (AP) view of a fractured Melody transcatheter pulmonary valve (TPV) within a right ventricular to pulmonary artery homograft. **b** AP view of a deployed Melody TPV within the previously fractured Melody valve after pre-stenting. **c** Transthoracic echocardiographic image with continuous wave (CW) Doppler across the fractured Melody TPV demonstrating moderate stenosis (peak velocity 3.6 m/s, peak gradient of 53 mmHg, and mean gradient 29 mmHg). **d** Transthoracic echocardiographic image with CW Doppler signal across the deployed Melody valve within the previously fractured Melody valve showing significant improvement (reduction in velocity to 2.3 m/s, peak gradient to 22 mmHg and mean gradient to 14 mmHg)Fig. 6Antero-posterior (AP) angiographic view of aortic root injection with simultaneous balloon inflation across the RVOT showing coronary artery compression (*black arrow*) of an anomalous left anterior descending arteryFig. 7**a** Antero-posterior (AP) angiographic view of aortic root injection prior to balloon inflation within a dysfunctional bioprosthetic pulmonary valve. **b** Aortic root injection with simultaneous balloon inflation across the pulmonary valve showing aortic root compression and the development of aortic regurgitation (*black arrow*)

Transcatheter pulmonary valve replacement has also been successfully performed within failed bioprosthetic valves, not as part of RV-PA conduits, with excellent outcomes including freedom from repeat intervention of 92 % at 1 year and 92 % at 2 years \[[@CR64]\]. The Melody valve can be utilized in most large diameter bioprostheses, up to a 24-mm maximal diameter, and the 26- or 29-mm Sapien valves can be used as well if the diameter is too large for a Melody valve \[[@CR65]\].

In the subset of congenital heart disease patients with native RVOT or RVOT patch repairs, there is a growing body of literature on the utility of commercially available valves used off-label. In a retrospective trial of 31 patients, Melody pulmonary valve implantation in native RVOT due to either stenosis or regurgitation was safe and feasible; however, there was a high stent fracture rate of 32 % despite pre-stenting \[[@CR66]\]. Boudjemline et al \[[@CR67]\] showed that for patients with large RVOT, multiple stenting in Russian-doll style or jailing the PA method can create a suitable landing zone for the transcatheter valve (Fig. [8](#Fig8){ref-type="fig"}). Off-label use of the larger-diameter 29-mm Sapien XT and S3 valves in large native RVOT is being performed in select patients, and newer valves are being developed specifically for that indication \[[@CR68]\].Fig. 8**a** Antero-posterior (AP) and cranial (CRA) angiographic view of a patient with transannular patch repair of the right ventricular outflow tract (RVOT) and main pulmonary artery (MPA) with a relative narrowing (*black arrow*) proximal to the bifurcation. The right ventricle (RV) is severely dilated. Right pulmonary arteries = RPA; left pulmonary artery = LPA. **b** Following pre-stenting with two stents, one extending into the LPA and "jailing" the RPA, but with open stent struts allowing antegrade bloodflow into the RPA. The Sapien transcatheter pulmonary valve (TPV) placement was deployed within the two stents. This technique allows for anchoring of the TPV in dilated RVOTs. Contrast injection in the LPA demonstrates a competent TPV without significant pulmonary regurgitation

The timing of pulmonary valve replacement in asymptomatic patients remains somewhat controversial \[[@CR17], [@CR25], [@CR52], [@CR53]\]. The advent of transcatheter valve therapies is in reality lowering the threshold for pulmonary valve replacement. Some experts argue that all patients with severe pulmonary regurgitation should undergo pulmonary valve replacement prior to the development of right ventricular dilation or dysfunction \[[@CR17]\]. This aggressive early intervention approach must be weighed against the procedural risks, the potential for infective endocarditis, and the potential decrease in the internal orifice diameter of surgically placed conduits or bioprosthetic valves with multiple transcatheter pulmonary valve implants over a patient's lifetime \[[@CR16]\].

Tricuspid Valve {#Sec12}
---------------

In congenital heart disease patients, prior surgical repair often involves annuloplasty rings with tricuspid valve repair, and less often tricuspid valve replacement. The risk of recurrent regurgitation in tricuspid valve repair is high and many will eventually require valve replacement \[[@CR69]\]. Bioprosthetic TVR is associated with valvular stenosis and/or regurgitation as a long-term consequence \[[@CR26], [@CR27]\]. Transcatheter tricuspid valve replacement is feasible, and there is a growing body of evidence for the use of both the Melody and Sapien valves in failing tricuspid valve rings or bioprostheses (Figs. [9](#Fig9){ref-type="fig"} and [10](#Fig10){ref-type="fig"}). The procedural success rate is high and immediate hemodynamic benefits are evident (Fig. [11](#Fig11){ref-type="fig"}); however, there is paucity of intermediate and long-term data \[[@CR70]--[@CR84]\]. The large-diameter Sapien valves have been successfully utilized in tricuspid annuloplasty rings and bands; however, the experience is limited to isolated case reports \[[@CR80]\].Fig. 9**a** Right anterior oblique (RAO) angiographic view of an inflated 30-mm balloon across a previously surgically placed incomplete tricuspid valve ring (*white arrow*). Simultaneous selective right coronary artery injection shows no evidence of compression. **b** Sapien transcatheter valve replacement (TVR) within the ring. **c** Transthoracic echocardiographic image (apical four-chamber view) with color Doppler flow showing severe tricuspid regurgitation across the native tricuspid valve. **d** Transthoracic echocardiographic image (apical four-chamber view) with color Doppler flow showing mild regurgitation across the Sapien valveFig. 10**a** Right anterior oblique (RAO) angiographic view of an inflated 30-mm Nucleus balloon (NuMED) across the surgically placed dysfunctional bioprosthetic Mosaic valve (Medtronic) in the tricuspid position. Simultaneous selective right coronary artery injection shows no evidence of compression. **b** Sapien valve being positioned across the bioprosthetic Mosaic valve. **c** RAO angiographic view of the deployed Sapien transcatheter valve in the tricuspid position. **d** Lateral angiographic view of the deployed Sapien valve in the tricuspid positionFig. 11**a** Invasive hemodynamic tracings of simultaneous right ventricular and right atrial pressures in a patient with atrial fibrillation and a stenotic bioprosthetic tricuspid valve showing elevated diastolic gradients (*shaded black area*)---mean gradient 8 mmHg. **b** Invasive hemodynamic tracings of right ventricular and right atrial pressures showing reduction of tricuspid stenosis to the mild range (mean gradient 3 mmHg) after transcutaneous valve placement. **c** Transthoracic echocardiographic image with CW Doppler across the tricuspid valve showing moderate stenosis (mean gradient 7 mmHg). **d** Transthoracic echocardiographic image with CW Doppler across the tricuspid valve demonstrating reduction of mean gradient to 3 mmHg after transcutaneous valve placement

In native valves, the MitraClip (Evalve) has been used from a transjugular approach; however, the tricuspid valve morphology (three leaflets and chordal attachments to the right ventricular wall) makes it more difficult to successfully position the Mitraclip \[[@CR60]\]. Other devices used include the Mitralign (Mitralign), a device originally designed to remodel the mitral annulus using pledgeted sutures, which has been successfully placed in some patients with severe tricuspid regurgitation \[[@CR85]\]. The TriCinch (4Tech) \[[@CR86]\], a percutaneous device designed for annular cinching of the tricuspid annulus, and the Millipede (Millipede), which involves the transcutaneous placement of a tricuspid annular ring with an attachment system, are still in pre-clinical trials.

Caval transcatheter valve implantation is another potential treatment option for severe tricuspid valve regurgitation, where valves are implanted in the superior and inferior vena cavae, with several case reports demonstrating hemodynamic success \[[@CR83], [@CR87], [@CR88]\]. Clinical trials are currently investigating Sapien XT implantation in the inferior vena cava in patients with severe tricuspid regurgitation at prohibitive surgical risk (HOVER Clinical Trial NCT02339974, and TRICAVAL Clinical Trial NCT02387697).

Conclusions {#Sec13}
===========

Right-sided transcatheter valvular implantation in patients with congenital heart disease and conduit or bioprosthetic valve dysfunction is not only gaining momentum with enormous potential for growth and innovation but is also quickly becoming the new standard of care. The minimally invasive and effective techniques of transcatheter valvular implantation have allowed for a reduction in the number of open cardiac surgeries that a patient with CHD can anticipate undergoing over a lifetime, therefore affecting the morbidity of this growing patient population. The use of TCPV in native RVOT is increasing, especially with the advent of large-diameter TCPV. There is a growing body of data on the efficacy and safety of transcatheter valve interventions in patients with tricuspid valve dysfunction. Pre-procedural planning with the use of multiple imaging modalities is integral to procedural success, and it is critical to combine both structural and functional data for determining the correct timing of any intervention. An interdisciplinary team approach is most ideal, with incorporation of hybrid procedures using both surgical and catheter-based techniques. A larger body of evidence with intermediate and long-term outcomes is needed to assess the longevity of these new techniques in comparison to the current surgical gold standard.
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